For the current quarter, analysts are expecting Continental Resources, Inc. (NYSE:CLR) to report EPS of $N/A. This consensus estimate is provided by Zacks Research. After the period that ended on N/A, Continental Resources, Inc. (NYSE:CLR) reported an EPS actual of $N/A. The difference between the actual and estimate resulted in a surprise factor of N/A%. The company is expected to release their next earnings report on or around N/A. Interested parties will be watching to see how company results compare to what the Street was projecting for the fiscal period.
Shares of Continental Resources, Inc. (NYSE:CLR) have a current ABR or average broker rating of N/A. This consensus recommendation is also provided by Zacks Research. The recommendation falls on a scale between 1 and 5. A broker rating of 1 would translate into a Strong Buy. A rating of 5 would indicate a Strong Sell recommendation. This consensus broker rating may help shed some light on how the sell-side is currently viewing company stock.
Covering analysts often provide target price projections for company shares. The current Zacks consensus target price on shares of Continental Resources, Inc. (NYSE:CLR) is $N/A. The top analyst target is $N/A, and the lowest target is $N/A on the stock. Because of the different techniques used to gauge a company target price, estimates may be quite different from one analyst to another.
Wall Street sell-side research analysts covering Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) shares have recently provided various price target projections on where the stock might be going. According to them, the stock is expected to reach $N/A on a consensus level within the next year, according to Zacks. The most bullish estimate sees the stock reaching $N/A while the most conservative estimate stand at $N/A.
Zacks also gives an average broker rating based on the sell-side recommendations from the analysts who cover Intercept Pharmaceuticals, Inc.. They give the company shares an ABR of N/A. This is based on the N/A analysts taken into consideration by Zacks.
Earnings Estimates for Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)
Currently, Wall Street is projecting that the firm will post $N/A earnings per share. This consensus number is also derived from Zacks. For the most recent period which ended on N/A, Intercept Pharmaceuticals, Inc.'s EPS was reported as $N/A. This created a “surprise factor” N/A% due to being $N/A apart from what Wall Street predicted. When actual numbers differ greatly from the consensus expectations, sharp movement in the stock price can often be seen in the hours or days following the report.
Investors will mark their calendars for N/A, the date when Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) are expected to release their quarterly results.